
    
      To evaluate the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR)
      compared with placebo plus BR based on Independent Review Committee (IRC) assessment of
      progression-free survival (PFS) per the Lugano Classification for Non-Hodgkin Lymphoma (NHL)
      in subjects with previously untreated mantle cell lymphoma (MCL).
    
  